Abel Hall, LLC Adagio Therapeutics, Inc. Transaction History
Abel Hall, LLC
- $166 Billion
- Q1 2025
A detailed history of Abel Hall, LLC transactions in Adagio Therapeutics, Inc. stock. As of the latest transaction made, Abel Hall, LLC holds 10,074 shares of ADGI stock, worth $33,344. This represents 0.0% of its overall portfolio holdings.
Number of Shares
10,074Holding current value
$33,344% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding ADGI
# of Institutions
77Shares Held
70.6MCall Options Held
3.6KPut Options Held
2.1K-
Lee Ainslie Maverick Capital LTD | Dallas, Tx11.8MShares$38.9 Million0.75% of portfolio
-
Mithril Ii Gp LP Austin, TX11.2MShares$37.2 Million30.95% of portfolio
-
Deep Track Capital, LP Greenwich, CT10.7MShares$35.4 Million1.56% of portfolio
-
M28 Capital Management LP Stamford, CT9.25MShares$30.6 Million24.88% of portfolio
-
Black Rock Inc. New York, NY4.47MShares$14.8 Million0.0% of portfolio
About Adagio Therapeutics, Inc.
- Ticker ADGI
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 108,831,000
- Market Cap $505M
- Description
- Adagio Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company's lead product candidate is the ADG20 (adintrevimab), a neutralizing antibody that is in Phase 3 clinical trials for the treatmen...